

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr **TWYNSTA**[®]

Telmisartan / Amlodipine (as Amlodipine Besylate) Tablets

Tablet, 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg, Oral

Angiotensin II AT1 Receptor Blocker / Calcium Channel Blocker

Boehringer Ingelheim (Canada) Ltd.
5180 South Service Road
Burlington, Ontario
L7L 5H4

Date of Initial Authorization:
AUG 11, 2011

Date of Revision:
October 4, 2022

Submission Control Number: 264045

BICL CCDS#0275-08

Twynsta[®] is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd.

RECENT MAJOR LABEL CHANGES

| | |
|-----------------------------|---------|
| 4 DOSAGE AND ADMINISTRATION | 10/2022 |
| 7 WARNINGS AND PRECAUTIONS | 10/2022 |

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

| | |
|--|----|
| RECENT MAJOR LABEL CHANGES | 2 |
| TABLE OF CONTENTS | 2 |
| PART I: HEALTH PROFESSIONAL INFORMATION | 4 |
| 1 INDICATIONS | 4 |
| 1.1 Pediatrics | 4 |
| 1.2 Geriatrics | 4 |
| 2 CONTRAINDICATIONS | 4 |
| 3 SERIOUS WARNINGS AND PRECAUTIONS BOX | 5 |
| 4 DOSAGE AND ADMINISTRATION | 5 |
| 4.2 Recommended Dose and Dosage Adjustment | 5 |
| 4.4 Administration | 6 |
| 4.5 Missed Dose | 6 |
| 5 OVERDOSAGE | 7 |
| 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING | 7 |
| 7 WARNINGS AND PRECAUTIONS | 8 |
| 7.1 Special Populations | 12 |
| 7.1.1 Pregnant Women | 12 |
| 7.1.2 Breast-feeding | 13 |
| 7.1.3 Pediatrics | 14 |
| 7.1.4 Geriatrics | 14 |
| 8 ADVERSE REACTIONS | 14 |
| 8.1 Adverse Reaction Overview | 14 |
| 8.2 Clinical Trial Adverse Reactions | 15 |
| 8.3 Less Common Clinical Trial Adverse Reactions | 18 |

| | | |
|-----------|--|-----------|
| | 8.5 Post-Market Adverse Reactions | 19 |
| 9 | DRUG INTERACTIONS | 20 |
| | 9.1 Serious Drug Interactions | 20 |
| | 9.2 Drug Interactions Overview | 20 |
| | 9.3 Drug Behavioural Interactions | 21 |
| | 9.4 Drug-Drug Interactions | 21 |
| | 9.5 Drug-Food Interactions | 27 |
| | 9.6 Drug-Herb Interactions | 28 |
| | 9.7 Drug-Laboratory Test Interactions | 28 |
| 10 | CLINICAL PHARMACOLOGY | 28 |
| | 10.1 Mechanism of Action | 28 |
| | 10.2 Pharmacodynamics | 29 |
| | 10.3 Pharmacokinetics | 31 |
| 11 | STORAGE, STABILITY AND DISPOSAL | 35 |
| 12 | SPECIAL HANDLING INSTRUCTIONS | 35 |
| | PART II: SCIENTIFIC INFORMATION | 36 |
| 13 | PHARMACEUTICAL INFORMATION | 36 |
| 14 | CLINICAL TRIALS | 37 |
| | 14.1 Clinical Trials by Indication | 37 |
| | 14.2 Comparative Bioavailability Studies | 47 |
| 15 | MICROBIOLOGY | 40 |
| 16 | NON-CLINICAL TOXICOLOGY | 40 |
| | PATIENT MEDICATION INFORMATION | 44 |

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

TWYNSTA (telmisartan/amlodipine besylate) is indicated for:

- treatment of mild to moderate essential hypertension for whom combination therapy with telmisartan and amlodipine is appropriate.

TWYNSTA is not indicated for initial therapy (see 4 [DOSAGE AND ADMINISTRATION](#)).

1.1 Pediatrics

- **Pediatrics (<18 years of age):** Based on the data submitted and reviewed by Health Canada, the safety and efficacy of TWYNSTA in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

- **Geriatrics (> 65 years of age):** No dose adjustment is necessary for geriatric patients. It should be recognized, however, that greater sensitivity in some older individuals cannot be ruled out.

2 CONTRAINDICATIONS

TWYNSTA (telmisartan/amlodipine besylate) is contraindicated in:

- Concomitant use of angiotensin receptor blockers (ARBs) –including the telmisartan component of TWYNSTA- with aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR < 60 ml/min/1.73m²) is contraindicated (see 7 [WARNINGS AND PRECAUTIONS, Cardiovascular, Dual Blockade of the Renin-Angiotensin System \(RAS\)](#) and [Renal](#), and 9 [DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin System \(RAS\) with ACEIs, ARBs or aliskiren-containing drugs](#)).
- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#) section of the product monograph
- Patients with a hypersensitivity to dihydropyridine derivatives
- Patients with a known hypersensitivity (anaphylaxis) or angioedema to ARBs (see 7 [WARNINGS AND PRECAUTIONS, General](#))
- Pregnant women (see [7.1.1 Pregnant Women](#))
 - When used in pregnancy, angiotensin receptor (AT₁) blockers (ARB) can cause injury or even death of the developing fetus. When pregnancy is detected, TWYNSTA should be discontinued as soon as possible.

- Breast-feeding women (see [7.1.2 Breast-feeding](#))
- Patients with biliary obstructive disorders
- Patients with severe hepatic impairment
- Patients with shock including cardiogenic shock
- Severe hypotension
- Obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis)
- Haemodynamically unstable heart failure after acute myocardial infarction
- Patients with rare hereditary conditions that may be incompatible with an excipient of the product
- Patients with the rare hereditary condition of fructose intolerance (HFI)
 - Sorbitol: Sorbitol is a source of fructose. TWYNSTA tablets 80/5 mg and 80/10 mg contain 337.28 mg of sorbitol in each tablet.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

When used in pregnancy, angiotensin receptor (AT₁) blockers (ARB) can cause injury or even death of the developing fetus. When pregnancy is detected, TWYNSTA should be discontinued as soon as possible (see WARNINGS AND PRECAUTIONS, Special Populations).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

Patients should be titrated on individual drugs. If the fixed dose combination represents the dose and dosing frequency determined by this titration, the use of TWYNSTA may be more convenient in the management of patients. If during maintenance therapy dosage adjustment is necessary, it is advisable to use the individual drugs.

4.2 Recommended Dose and Dosage Adjustment

- TWYNSTA should be taken once daily.
- If during maintenance therapy dosage adjustment is necessary, it is advisable to use the individual drugs.

Replacement Therapy

- Patients receiving telmisartan and amlodipine from separate tablets can instead receive TWYNSTA containing the same component doses in one tablet once daily, e.g. to enhance convenience.

Special populations

Renal impairment

No dosage adjustment is required for patients with renal impairment, including those on haemodialysis.

Hepatic impairment

In patients with mild to moderate hepatic impairment TWYNSTA should be administered with caution. For telmisartan the dosage should not exceed 40 mg once daily as hepatic impairment increases bioavailability (see [Special Populations and Conditions - Hepatic insufficiency](#)).

Amlodipine dosage requirement have not been established in patients with impaired hepatic function. When amlodipine is used in these patients, it should be initiated at the lower end of the dosing range and the dosage should be carefully and gradually adjusted depending on the patient's tolerance and response.

Geriatrics (> 65 years of age)

No dose adjustment is necessary for elderly patients. It should be recognized, however, that greater sensitivity in some older individuals cannot be ruled out. If required, increase in the dose should be done gradually and with caution (see [7 WARNINGS AND PRECAUTIONS](#) and [10 CLINICAL PHARMACOLOGY](#)).

Pediatric population (<18 years of age)

TWYNSTA is not recommended for use in patients aged below 18 years due to a lack of data on safety and efficacy.

Drug discontinuation

If laryngeal stridor or angioedema of the face, extremities, lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the patient treated appropriately in accordance with accepted medical care, and carefully observed until the swelling disappears.

When pregnancy is detected, TWYNSTA should be discontinued as soon as possible.

4.4 Administration

Tablet for oral administration

TWYNSTA should be taken consistently with or without food. TWYNSTA tablets are for once-daily oral administration and should be swallowed whole with liquid.

4.5 Missed Dose

If a dose is missed during the day, the next dose should be continued at the usual time. Do not double dose.

5 OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Symptoms

TWYNSTA: There is no experience of overdose with *TWYNSTA*. Signs and symptoms of overdose are expected to be in line with exaggerated pharmacological effects.

Telmisartan: Limited data are available with regard to telmisartan overdose in humans. The most prominent manifestations of overdose were hypotension and/or tachycardia; bradycardia also occurred.

Amlodipine: Overdose with amlodipine may result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome may occur.

Therapy

If symptomatic hypotension should occur, supportive treatment should be instituted. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.

Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

| Route of Administration | Dosage Form / Strength/Composition | Non-medicinal Ingredients |
|-------------------------|--|--|
| oral | tablet 40/5 mg , 40/10 mg, 80/5 mg, 80/10 mg telmisartan/amlodipine | colloidal anhydrous silica, FD&C blue No 1 aluminium lake (E 133), ferric oxide black (E172), ferric oxide yellow (E172), magnesium stearate, maize starch, meglumine, microcrystalline cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol (E420). |

TWYNSTA is available as oval shaped, biconvex, uncoated, bilayer tablets with one layer white to off-white and the other layer blue. The white telmisartan layer is debossed with the BI

company logo and a code to differentiate between the different strengths (40/5 mg = A1, 40/10 mg = A2, 80/5 mg= A3 and 80/10 mg = A4).

Non-medicinal ingredients (in alphabetical order): colloidal anhydrous silica, FD&C blue No 1 aluminium lake (E 133), ferric oxide black (E172), ferric oxide yellow (E172), magnesium stearate, maize starch, meglumine, microcrystalline cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol (E420).

TWYNSTA tablets are packed in aluminium/aluminium blister cards in cartons of 28 tablets as 4 cards containing 7 tablets each.

Sorbitol

Sorbitol is a source of fructose.

TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each tablet.

TWYNSTA tablets 80/5 mg and 80/10 mg contain 337.28 mg sorbitol in each tablet and are contraindicated in patients with hereditary fructose intolerance (HFI) (see [2 CONTRAINDICATIONS](#)).

7 WARNINGS AND PRECAUTIONS

Please see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#).

General

A case of rare but fatal angioedema had occurred in a patient who had been medicated for about 6 months with telmisartan, one of the active components of TWYNSTA. The Autopsy Report described evidence of edema of the laryngeal mucosa, with terminal respiratory and circulatory failure. This is in the context of approximately 5.2 million patient-years exposure to telmisartan annually.

In instances where swelling is confined to the face and lips, the condition generally resolves without treatment, although antihistamines may be useful in relieving symptoms. Where there is involvement of tongue, glottis, or larynx, likely to cause airway obstruction, appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous epinephrine solution 1:1000) should be administered promptly (see [8.5 Post Market Adverse Drug Reactions; Telmisartan](#)).

Patients with a known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated with TWYNSTA (see [8.2 Clinical Trial Adverse Reactions - Unknown Frequencies, Immune System Disorders, Angioedema](#) and [8.5 Post Market Adverse Drug Reactions; Telmisartan](#)).

Beta-blocker withdrawal: TWYNSTA gives no protection against the dangers of abrupt beta-

blocker withdrawal and such withdrawal should be done by the gradual reduction of the dose of beta-blocker.

Cardiovascular

Ischaemic heart disease

As with any antihypertensive agent, excessive reduction of blood pressure in patients with ischaemic cardiopathy, ischaemic cardiovascular disease or patients with a history of cerebrovascular insufficiency could result in a myocardial infarction or stroke.

Aortic and Mitral Valve Stenosis, Obstructive Hypertrophic Cardiomyopathy

As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. These patients are at risk of decreased coronary perfusion resulting from a cardiac output that is limited by a fixed cardiac vascular obstruction.

Unstable Angina Pectoris, Acute Myocardial Infarction

There are no data to support the use of TWYNSTA in unstable angina pectoris and during or within one month of a myocardial infarction. Rarely, patients, particularly those with severe obstructive coronary artery disease, have developed increased frequency, duration and/or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. The mechanism of this effect has not been elucidated.

Patients with Cardiac Failure

In an amlodipine long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group. Therefore, patients with heart failure should be treated with caution.

Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.

Volume and/or sodium depleted patients

In patients who are volume-depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting, symptomatic hypotension may occur after initiation of therapy. Such conditions should be corrected before the administration of TWYNSTA.

Peripheral Edema

Peripheral edema is a recognised dose dependent side effect of amlodipine. In a single double blind, randomised, factorial clinical trial of eight weeks duration, edema was generally observed at a lower incidence in patients who received the telmisartan/amlodipine combination than in those who received amlodipine alone.

Dual blockade of the Renin-Angiotensin System (RAS)

There is evidence that co-administration of angiotensin receptor blockers (ARBs), such as the telmisartan component of TWYNSTA, or of angiotensin-converting-enzyme inhibitors (ACEIs) with aliskiren increases the risk of hypotension, syncope, stroke, hyperkalemia and deterioration of renal function, including renal failure, in patients with diabetes mellitus (type 1 or type 2) and/or moderate to severe renal impairment (GFR < 60 ml/min/1.73m²). Therefore, the use of TWYNSTA in combination with aliskiren-containing drugs is contraindicated in these patients.

Further, co-administration of ARBs, including the telmisartan component of TWYNSTA, with other agents blocking the RAS, such as ACE inhibitors or aliskiren-containing drugs, is generally not recommended in other patients, since such treatment has been associated with an increased incidence of severe hypotension, renal failure, and hyperkalemia.

Diabetic Patients

In diabetic patients with undiagnosed coronary artery disease (CAD) on blood pressure lowering therapy, the risk of fatal myocardial infarction and unexpected cardiovascular death may be increased. In patients with diabetes mellitus, CAD may be asymptomatic and therefore undiagnosed. These patients should undergo appropriate diagnostic evaluation, e.g. exercise stress testing, to detect and to treat CAD accordingly before initiating blood pressure lowering treatment with TWYNSTA.

Driving and Operating Machinery

No studies on the effect on the ability to drive and use machines have been performed. However, when driving vehicles or operating machinery it should be taken into account that dizziness, syncope or vertigo may occasionally occur when taking antihypertensive therapy.

If patients experience these adverse events, they should avoid potentially hazardous tasks such as driving or operating machinery.

Endocrine and Metabolism

Hyperkalaemia

Drugs such as TWYNSTA that affect the renin-angiotensin-aldosterone system can cause hyperkalemia. Monitoring of serum potassium in patients at risk is recommended. Based on experience with the use of drugs that affect the renin-angiotensin system, concomitant use with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or medicinal products that may increase potassium levels (heparin, etc.) may lead to a greater risk of an increase in serum potassium and should therefore be co-administered cautiously with telmisartan.

Hepatic/Biliary/Pancreatic

Hepatic Impairment

As the majority of telmisartan is eliminated by biliary excretion, patients with cholestasis,

biliary obstructive disorders or hepatic insufficiency have reduced clearance of telmisartan leading to increased systemic exposure. Three to four fold increases in C_{max} and AUC of telmisartan were observed in patients with liver impairment as compared to healthy subjects. The half-life of amlodipine is prolonged to 56 h and AUC values are 40-60% higher in patients with impaired liver function. Amlodipine should therefore be initiated at the lower end of the dosing range and titration should be slow, with careful monitoring throughout. TWYNSTA should be used with caution in these patients.

Use in patients with severe hepatic impairment is contraindicated (see [2 CONTRAINDICATIONS](#)).

Monitoring and Laboratory Tests

For specific monitoring and laboratory tests, see [7 WARNINGS AND PRECAUTIONS, Cardiovascular, Endocrine and Metabolism, Hepatic, and Renal](#) and [9 DRUG INTERACTIONS](#) sections.

Renal

Renovascular Hypertension

There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.

Renal Impairment and Kidney Transplant

When TWYNSTA is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of TWYNSTA in patients with a recent kidney transplant. Telmisartan is not removed from blood by hemofiltration and is not dialyzable. Amlodipine is not dialyzable.

Blockade of the Renin-Angiotensin-Aldosterone System

In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, dual blockade (e.g. concomitant use of an angiotensin II receptor blocker with an ACE inhibitor or the direct renin-inhibitor aliskiren) or treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely acute renal failure and/or death. Upon treatment in such cases, renal function should be closely monitored. However, TWYNSTA can be administered with other antihypertensive drugs.

Primary Aldosteronism

Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of TWYNSTA is not recommended.

Renal Impairment

The use of ARBs – including the telmisartan component of TWYNSTA – or of ACEIs with aliskiren-containing drugs is contraindicated in patients with moderate to severe renal impairment (GFR < 60 ml/min/1.73m²). (See [2 CONTRAINDICATIONS](#) and [9 DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin System \(RAS\) with ARBs, ACEIs, or aliskiren-containing drugs](#)).

Concomitant Use with Strong Inhibitors of CYP 3A4

Use of TWYNSTA with drugs that result in strong inhibition of CYP 3A4, such as ketoconazole, clarithromycin, ritonavir, may lead to increased plasma levels of amlodipine and associated serious adverse events (see DRUG INTERACTIONS). Such concomitant use should be avoided. An observational study demonstrated an increased risk of hospitalisation with acute kidney injury when amlodipine was used concomitantly with clarithromycin in elderly patients (>65 years of age) compared to when it was used concomitantly with azithromycin, odds ratio [amlodipine: 1.61 (95% C.I. 1.29 - 2.02)].

Reproductive Health: Female and Male Potential

• **Fertility**

No studies on fertility in humans with the fixed dose combination or with the individual components have been performed. Separate reproductive toxicity studies with the combination of telmisartan and amlodipine have not been conducted (See [16 NON-CLINICAL TOXICOLOGY, Telmisartan, Amlodipine](#)).

In some patients treated by calcium channel blockers, reversible biochemical changes in the head of spermatozoa have been reported.

Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (See [16 NON-CLINICAL TOXICOLOGY, Telmisartan, Amlodipine](#)).

7.1 Special Populations

7.1.1 Pregnant Women

TWYNSTA

While the effects of TWYNSTA during pregnancy are not known, treatment should be discontinued as soon as a pregnancy is detected due to the telmisartan component of this combination drug.

Telmisartan

Drugs that act directly on the renin-angiotensin-aldosterone-system (RAAS) can cause fetal and neonatal morbidity and death when administered to pregnant women.

The use of angiotensin receptor (AT₁) blockers (ARBs) is not recommended during pregnancy and should not be initiated during pregnancy. Epidemiological evidence regarding the risk of

teratogenicity following exposure to angiotensin converting enzyme inhibitors (another class of therapeutic products interfering with the RAAS) during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Given the current evidence available on the risk with ARB, similar risks may exist for this class of drugs. Patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.

Preclinical studies with telmisartan do not indicate teratogenic effect, but have shown fetotoxicity.

The use of ARBs during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalemia).

Infants with a history of in utero exposure to ARBs should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion may be required as a means of reversing hypotension and/or substituting for disordered renal function; however, limited experience with those procedures has not been associated with significant clinical benefit.

No teratogenic effects were observed when telmisartan was administered to pregnant rats at oral doses of up to 50 mg/kg/day and to pregnant rabbits at oral doses up to 45 mg/kg/day with saline supplementation. In rabbits, fetotoxicity (total resorptions) associated with maternal toxicity (reduced body weight gain, mortality) was observed at the highest dose level (45 mg/kg/day). In rats, maternally toxic (reduction in body weight gain and food consumption) telmisartan doses of 50 mg/kg/day in late gestation and during lactation were observed to produce adverse effects in rat fetuses and neonates, including reduced viability, low birth weight, delayed maturation, and decreased weight gain (see [16 NON-CLINICAL TOXICOLOGY, Telmisartan, Reproduction](#)). Significant levels of telmisartan were present in rat milk and rat fetuses' blood during late gestation.

Amlodipine

Although amlodipine was not teratogenic in the rat and rabbit some dihydropyridine compounds have been found to be teratogenic in animals. In rats, amlodipine has been shown to prolong both the gestation period and the duration of labor. There is no clinical experience with amlodipine in pregnant women.

7.1.2 Breast-feeding

TWYNSTA is contraindicated during breast feeding. It is not known whether telmisartan is excreted in human milk but significant levels have been found in the milk of lactating rats (see [2 CONTRAINDICATIONS](#)).

Amlodipine is transferred into human breast milk and therefore its use is contraindicated

during breast feeding. The minimum proportion of the maternal dose received by the infant has been estimated to be between 3 and 15% and this might vary according to breastmilk composition.

A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother (see [2 CONTRAINDICATIONS](#)).

7.1.3 Pediatrics

Pediatrics (< 18 years of age): TWYNSTA is not recommended for use in patients aged below 18 years due to a lack of data on safety and efficacy.

7.1.4 Geriatrics

Geriatrics (> 65 years of age): In geriatric patients (≥ 65 years) clearance of amlodipine is decreased with a resulting increase in AUC (see [10.3 Pharmacokinetics](#)). In clinical trials for amlodipine, the incidence of adverse reactions in elderly patients was approximately 6% higher than that of younger population (<65 years). Adverse reactions include edema, muscle cramps and dizziness. TWYNSTA should be used cautiously in elderly patients.

The increase of the amlodipine dosage should take place with care in the elderly patients (see sections [4 DOSAGE AND ADMINISTRATION](#) and [10 CLINICAL PHARMACOLOGY](#)).

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Summary of the safety profile

The safety and tolerability of TWYNSTA has been evaluated in five controlled clinical studies with over 3500 patients, over 2500 of whom received telmisartan in combination with amlodipine.

No additional adverse reactions were identified in clinical trials with the combination telmisartan plus amlodipine compared to the adverse reactions of the monocomponents. Peripheral oedema, a recognized dose dependent adverse reaction of the monocomponent amlodipine, was generally observed at a lower incidence in patients who received the telmisartan/amlodipine combination than in those who received amlodipine alone.

Adverse reactions previously reported with one of the monocomponents (telmisartan or amlodipine) may be potential adverse reactions with TWYNSTA as well, even if not observed in clinical trials or during the post-marketing period. Therefore, in addition to the reported adverse reactions during the TWYNSTA development program all adverse reactions reported in patients who received telmisartan or amlodipine monotherapy, have been listed for TWYNSTA.

Combination therapy showed a favourable safety profile, with lower edema rates than amlodipine monotherapies, especially when comparing amlodipine full -dose monotherapy with amlodipine low-dose combinations, which showed at least comparable or better efficacy.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Adverse events potentially related to BP lowering (e.g. hypotension, orthostatic hypotension, syncope) were rare throughout the double-blind treatment period of a randomized, double-dummy, placebo-controlled 4x 4 factorial design trial, including the initial 2 weeks of first-line combination therapy. There were no serious cases. Almost all of the events were of mild or moderate intensity, and the majority of patients continued treatment and recovered without requiring therapy.

In a single, randomized double-blind placebo controlled, 8-week factorial design comparing free dose combination telmisartan/amlodipine to monotherapy (telmisartan or amlodipine) and placebo, adverse events (AEs) occurred with similar frequency across the treatment groups, with the highest frequency in the telmisartan 80mg/amlodipine 5 mg (T80/A5) group but the incidence of all AEs, in all groups was within 4% of the placebo group. Three serious adverse events occurred in the T80/A5 group, none of which were felt to be drug related. The three serious adverse events occurred in 3 different patients and included multiple fractures, deep venous thrombosis, and chest pain (see Table 2).

Table 2: Summary of adverse events by overall treatment groups in the factorial study.

| | T40/A5 | T40/A10 | T80/A5 | T80/A10 | T40 | T80 | A5 | A10 | Placebo |
|---|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| <i>Incidence over entire study: No. treated</i> | 143 | 129 | 146 | 142 | 130 | 135 | 140 | 129 | 46 |
| Any adverse event (AE) | 47 (32.9) | 48 (37.2) | 54 (37.0) | 62 (43.7) | 47 (36.2) | 47 (34.8) | 50 (35.7) | 51 (39.5) | 18 (39.1) |
| Severe AEs | 3 (2.1) | 2 (1.6) | 4 (2.7) | 5 (3.5) | 2 (1.5) | 3 (2.2) | 7 (5.0) | 2 (1.6) | 0 (0.0) |
| AEs considered drug-related | 19 (13.3) | 16 (12.4) | 17 (11.6) | 27 (19.0) | 11 (8.5) | 7 (5.2) | 12 (8.6) | 22 (17.1) | 6 (13.0) |
| Other significant AEs ¹ | 0 (0.0) | 5 (3.9) | 3 (2.1) | 6 (4.2) | 2 (1.5) | 3 (2.2) | 3 (2.1) | 3 (2.3) | 2 (4.3) |

| | T40/A5 | T40/A10 | T80/A5 | T80/A10 | T40 | T80 | A5 | A10 | Placebo |
|--|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| AEs leading to discontinuation of study drug | 0 (0.0) | 5 (3.9) | 4 (2.7) | 6 (4.2) | 2 (1.5) | 4 (3.0) | 3 (2.1) | 3 (2.3) | 2 (4.3) |
| Serious AEs ² | 0 (0.0) | 0 (0.0) | 3 (2.1) | 0 (0.0) | 0 (0.0) | 1 (0.7) | 1 (0.7) | 0 (0.0) | 0 (0.0) |
| Fatal | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Immediately life-threatening | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Caused disability or incapacity | 0 (0.0) | 0 (0.0) | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Required hospitalization | 0 (0.0) | 0 (0.0) | 2 (1.4) | 0 (0.0) | 0 (0.0) | 1 (0.7) | 1 (0.7) | 0 (0.0) | 0 (0.0) |

¹ Marked laboratory abnormalities or AEs leading to intervention, other than those considered serious

² A patient may be counted in more than one seriousness criterion

T = Telmisartan 40 or 80 mg; A = amlodipine 5 or 10 mg.

In the single, randomized double-blind placebo controlled, 8-week factorial design comparing free dose combination telmisartan (T, 40 or 80 mg) and amlodipine (A, 5 or 10 mg) to monotherapy (telmisartan or amlodipine) and placebo, adverse events (AEs) occurred with similar frequency across the treatment groups, the most frequent AE overall, peripheral edema, was reported for higher percentages of patients in treatment groups containing A10 than in the other groups, with lower frequencies in the A10 combination groups (T40/A10 6.2%, T80/A10 11.3%) than in the A10 monotherapy group (17.8%). Patient frequencies of some common AEs were higher in some combination groups than in the respective component monotherapy groups, but no consistent patterns were apparent (see Table 3). Other than these events (i.e. peripheral edema, headache and fatigue), all drug-related AEs were reported by <1% of patients in any treatment group.

Additional data on long term safety was based on an open-label, limited study, of 6 month up to 8 months duration and no new safety signals were noted.

Table 3: Adverse events with reported incidence $\geq 2\%$ than in the placebo group of patients (N=46) in the factorial study

| MedDRA system organ class | T40/A5 (N=143) | T40/A10 (N=129) | T80/A5 (N=146) | T80/A10 (N=142) | T40 (N=130) | T80 (N=135) | A5 (N=140) | A10 (N=129) |
|---------------------------|----------------|-----------------|----------------|-----------------|-------------|-------------|------------|-------------|
| Preferred term | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| | | | | | | | | |

| | | | | | | | | |
|---|----|----|----|----|----|----|----|----|
| Total with any adverse events | 33 | 38 | 37 | 44 | 36 | 35 | 36 | 40 |
| Gastrointestinal disorders | | | | | | | | |
| Nausea | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 1 |
| General disorders and administration site conditions | | | | | | | | |
| Chest discomfort/Chest pain | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 1 |
| Fatigue | 2 | 0 | 1 | 1 | 2 | 3 | 1 | 1 |
| Edema | 0 | 3 | 1 | 2 | 0 | 0 | 1 | 2 |
| Edema peripheral | 1 | 6 | 2 | 11 | 1 | 1 | 1 | 18 |
| Infections and infestations | | | | | | | | |
| Influenza | 1 | 1 | 3 | 2 | 0 | 0 | 1 | 2 |
| Upper respiratory tract infection | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 2 |
| Metabolism and nutrition disorders | | | | | | | | |
| Hypokalemia* | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | | | | | | |
| Back pain | 3 | 3 | 1 | 2 | 0 | 2 | 4 | 1 |
| Muscle spasms | 0 | 1 | 0 | 2 | 2 | 0 | 1 | 1 |
| Myalgia | 0 | 1 | 0 | 1 | 0 | 2 | 2 | 0 |
| Nervous system disorders | | | | | | | | |
| Dizziness | 5 | 2 | 4 | 1 | 1 | 1 | 3 | 0 |

T = Telmisartan 40 or 80 mg

A = amlodipine 5 or 10 mg

* Coincidental

Common Clinical Trial Adverse Drug Reactions- telmisartan and amlodipine combination therapy (> 1%)

General Disorders: edema peripheral

Nervous System Disorders: dizziness

8.3 Less Common Clinical Trial Adverse Reactions

Less Common Clinical Trial Adverse Drug Reactions (<1%) for telmisartan and amlodipine combination therapy

Blood and the Lymphatic System Disorders: anemia, eosinophilia, thrombocytopenia

Cardiac Disorders: bradycardia, palpitations, tachycardia

Ear and Labyrinth Disorders: vertigo

Eye Disorders: visual impairment

Gastrointestinal Disorders: abdominal pain, diarrhea, vomiting, nausea, gingival hypertrophy, dyspepsia, dry mouth, flatulence, abdominal discomfort

General Disorders: asthenia (weakness), chest pain, fatigue, edema, malaise, influenza like illness

Hepato-Biliary Disorders: hepatic function abnormal, liver disorder

Immune System Disorders: hypersensitivity, anaphylactic reaction

Infections and Infestations: cystitis, sepsis including fatal outcome, urinary tract infections, upper respiratory tract infections

Investigations: hepatic enzyme increased, blood uric acid increased, hemoglobin decreased, blood creatinine increased, blood creatinine phosphokinase (CPK) increased

Metabolism and Nutrition Disorders: hyperkalemia, hypoglycemia (in diabetic patients)

Musculoskeletal and Connective Tissue Disorders: arthralgia, back pain, muscle spasms (cramps in leg), myalgia, pain in extremity (leg pain), tendon pain (tendinitis like symptoms)

Nervous System Disorders: syncope (faint), somnolence, migraine, headache, neuropathy peripheral, paraesthesia, hypoaesthesia, dysgeusia, tremor

Psychiatric disorders: depression, anxiety, insomnia

Renal and Urinary Disorders: nocturia, renal impairment (including acute kidney injury)

Reproductive System and Breast Disorders: erectile dysfunction,

Respiratory, Thoracic and Mediastinal Disorders: cough, dyspnea

Skin and Subcutaneous Tissue Disorders: eczema, erythema, rash, pruritus, drug eruption, toxic skin eruption, hyperhidrosis, urticaria, angioedema

Vascular Disorders: hypotension, orthostatic hypotension, flushing

Less Common Clinical Trial Adverse Drug Reactions (<1%) for Amlodipine

The following adverse reactions may be expected based on experience with amlodipine, but not yet observed with this fixed dose combination:

Blood and the Lymphatic System Disorders: leukopenia

Cardiac Disorders: myocardial infarction, arrhythmia, ventricular tachycardia, atrial fibrillation, cardiac failure

Ear and Labyrinth Disorders: tinnitus

Eye Disorders: diplopia

Gastrointestinal Disorders: change of bowel habit, pancreatitis, gastritis, constipation, dysphagia

General Disorders: pain, weight increased, weight decreased, rigors

Hepato-Biliary Disorders: hepatitis, jaundice, hepatic enzyme increased (mostly consistent with cholestasis)

Immune System Disorders: hypersensitivity

Metabolism and Nutrition Disorders: hyperglycaemia

Musculoskeletal and Connective Tissue Disorders: joint swelling

Nervous system disorders: extrapyramidal disorder, hypertonia

Psychiatric Disorders: mood altered, confusional state, nervousness

Renal and Urinary Disorders: micturition disorder, pollakiuria

Reproductive System and Breast Disorders: gynecomastia

Respiratory, Thoracic and Mediastinal Disorders: rhinitis, epistaxis

Skin and Subcutaneous Tissue Disorders: alopecia, purpura, skin discolouration, erythema multiforme, dermatitis exfoliative, photosensitivity reaction, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema with breathing difficulties

Vascular Disorders: vasculitis, peripheral ischemia

8.5 Post-Market Adverse Reactions

Post-market adverse drug reactions are listed below for the respective monotherapies. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Telmisartan

Since the introduction of telmisartan in the market, cases of anxiety, dizziness, vision trouble, vertigo, abdominal distension, abdominal pain, retching, hyperhidrosis, arthralgia, myalgia, muscle spasm, back pain, asthenia, pain in extremity, fatigue, chest pain, blood creatinine increased, erythema, pruritus, syncope/faint, insomnia, depression, abdominal discomfort, vomiting, hypotension (including orthostatic hypotension), bradycardia, tachycardia, abnormal hepatic function/liver disorder, renal impairment including acute kidney injury, hyperkalemia, dyspnoea, anaemia, eosinophilia, thrombocytopenia, hyponatraemia and weakness have been reported. The frequency of these effects is unknown. As with other angiotensin II blockers, rare cases of angioedema (including fatal outcome), pruritus, rash and urticaria have been reported.

Cases of muscle pain, muscle weakness, myositis and rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers.

In addition, since the introduction of telmisartan in the market, cases with increased blood creatinine phosphokinase (CPK) have been reported.

Amlodipine

In post marketing experience, jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis) in some cases severe enough to require hospitalization have been reported in association with use of amlodipine.

9 DRUG INTERACTIONS

9.1 Serious Drug Interactions

Serious Drug Interactions

- Concomitant use of angiotensin receptor blockers (ARBs) –including the telmisartan component of TWYNSTA- with aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR < 60 ml/min/1.73m²) is contraindicated (see 7 [WARNINGS AND PRECAUTIONS, Cardiovascular, Dual Blockade of the Renin-Angiotensin System \(RAS\)](#) and [Renal](#), and 9 [DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin System \(RAS\) with ACEIs, ARBs or aliskiren-containing drugs](#)).

9.2 Drug Interactions Overview

No interactions between the two components of this fixed dose combinations have been observed in clinical studies.

No new drug interaction studies have been performed with TWYNSTA and other medicinal

products.

Amlodipine

Dihydropyridine calcium channel blockers undergo biotransformation by the cytochrome P450 system, mainly via CYP 3A4 isoenzyme. Coadministration of amlodipine with other drugs which follow the same route of biotransformation may result in altered bioavailability of amlodipine or these drugs. Dosages of similarly metabolized drugs, particularly those of low therapeutic ratio, and especially in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping concomitantly administered amlodipine to maintain optimum therapeutic blood levels.

9.3 Drug- Behavioural Interactions

Interactions with lifestyle have not been established.

9.4 Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Coadministration of telmisartan also did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, or hydrochlorothiazide.

Table 4: Established or Potential Drug-Drug Interactions in telmisartan + amlodipine

| Telmisartan + Amlodipine | Source of evidence | Effect | Clinical comment |
|---|---------------------------|--|---|
| Other antihypertensive agents | T | The blood pressure lowering effect of TWYNSTA can be increased by concomitant use of other antihypertensive medicinal products. | To be taken into account with concomitant use |
| Agents with blood pressure lowering potential | T | Based on their pharmacological properties it can be expected that the following medicinal products may potentiate the hypotensive effects of all antihypertensives including TWYNSTA, e.g. baclofen, amifostine. Furthermore, orthostatic hypotension may be aggravated by alcohol, barbiturates, narcotics, or antidepressants. | To be taken into account with concomitant use |
| Corticosteroids (systemic route) | T | Reduction of the antihypertensive effect. | To be taken into account with concomitant use |

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

Table 5: Established or Potential Drug-Drug Interactions in telmisartan

| Telmisartan | Source of evidence | Effect | Clinical comment |
|--|--------------------------|--|--|
| Agents increasing serum potassium | T | Telmisartan component of TWYNSTA reduces the production of aldosterone. | Potassium-sparing diuretics or potassium supplements should be given only for documented hypokalemia and with frequent monitoring of serum potassium. Potassium-containing salt substitutes should also be used with caution. Concomitant thiazide diuretic use may attenuate any effect that telmisartan may have on serum potassium. |
| Digoxin | CT | When telmisartan was co-administered with digoxin, mean increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. | It is recommended that digoxin levels be monitored with appropriate dose adjustments when initiating, adjusting or discontinuing TWYNSTA, to maintain appropriate plasma digoxin concentrations. |
| Diuretics | Hydrochlorothiazide (CT) | Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with telmisartan. | The possibility of symptomatic hypotension with the use of telmisartan can be minimized by discontinuing the diuretic prior to initiation of treatment and/or lowering the initial dose of telmisartan. No drug interaction of clinical significance has been identified with thiazide diuretics. |
| Dual Blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACEIs or aliskiren-containing drugs | T | The treatment has been associated with an increased incidence of severe hypotension, renal failure, and hyperkalemia. | Dual Blockade of the renin-angiotensin system (RAS) with ARBs, ACEIs or aliskiren-containing drugs is contraindicated in patients with diabetes and/or renal impairment, and is generally not recommended in other patients. See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS, Dual Blockade of the Renin-Angiotensin System (RAS) . |

| Telmisartan | Source of evidence | Effect | Clinical comment |
|---|---------------------------|---|---|
| Lithium salts | CT | Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Rare cases have also been reported with angiotensin II receptor blockers including telmisartan. | Serum lithium level monitoring is advisable during concomitant use. |
| Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | CT | Combinations of angiotensin-II blockers (telmisartan) and NSAIDs (including ASA and COX-2 inhibitors) might have an increased risk for acute renal failure and hyperkalemia. NSAIDs (including ASA and COX-2 inhibitors) and angiotensin-II receptor blockers exert a synergistic effect on the decrease of glomerular filtration. In patients with pre-existing renal impairment, this may lead to acute renal failure. | Blood pressure and kidney function should be monitored more closely in this situation, as occasionally there can be a substantial increase in blood pressure. Monitoring of renal function at the beginning and during the course of the treatment should be recommended. Co-administration of telmisartan did not result in a clinically significant interaction with ibuprofen. |
| Ramipril | CT | In one study, the co-administration of telmisartan and ramipril led to an increase of up to 2.5 fold in the AUC ₀₋₂₄ and C _{max} of ramipril and ramiprilat. | The clinical relevance of this observation is not known. |
| Warfarin | CT | Telmisartan administered for 10 days slightly decreased the mean warfarin trough plasma concentration. | The decrease in the mean warfarin trough plasma concentration did not result in a change in the International Normalized Ratio (INR). |

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

Table 6: Established or Potential Drug-Drug Interactions in amlodipine

| Amlodipine | Source of evidence | Effect | Clinical comment |
|--|--------------------|--|--|
| Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, azole antifungals, quinidine, terfenadine and warfarin) | CT T | Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients (69 to 87 years of age) resulted in a 57% increase in amlodipine systemic exposure. Erythromycin coadministration in healthy volunteers (18 to 43 years of age) increased the systemic exposure of amlodipine by 22%. | Concomitant use requiring caution. Clinical monitoring and dose adjustment may be required. These pharmacokinetic changes may be more pronounced in the elderly. |
| Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) Clarithromycin | T CT | May significantly increase the plasma concentrations of amlodipine to a greater extent than diltiazem. In elderly patients (>65 years of age), concomitant use of amlodipine with clarithromycin was associated with increased risk of hospitalization with acute kidney injury. | TWYNSTA should be used with caution together with CYP3A4 inhibitors and monitoring of therapy is required. Appropriate dosage adjustment of TWYNSTA may be necessary when used with CYP3A4 inhibitors. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis. Avoid concomitant administration of TWYNSTA with strong CYP3A4 inhibitors. (see 7 WARNINGS AND PRECAUTIONS) |
| CYP3A4 inducers (e.g., phenobarbital, phenytoin, rifampin) | T | There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers may give a lower plasma concentration of amlodipine which in turn can result in decreased | Concomitant use requiring caution TWYNSTA should be used with caution together with CYP3A4 inducers and dose adjustment may be necessary to maintain |

| Amlodipine | Source of evidence | Effect | Clinical comment |
|-------------------------------|--------------------|---|---|
| | | blood pressure lowering effects. | efficacy. Blood pressure should be monitored and dose adjustment considered both during and after concomitant administration, particularly with strong CYP3A4 inducers (e.g., rifampicin, hypericum perforatum). Hence, monitoring of therapy is required. |
| Cimetidine, warfarin, digoxin | CT | Not Applicable. | Pharmacokinetic interaction studies with amlodipine in healthy volunteers have indicated that cimetidine did not alter the pharmacokinetics of amlodipine and that amlodipine did not change warfarin-induced prothrombin response time nor did it change serum digoxin levels or digoxin renal clearance in normal volunteers. |
| Antacids | CT | Not Applicable. | Concomitant administration of Maalox® (magnesium hydroxide and aluminum hydroxide) had no effect on the disposition of a single 5 mg dose of amlodipine in 24 subjects. |
| Beta-blockers | T | Blood pressure lowering effect of beta-blockers may be increased by amlodipine. | When beta-adrenergic receptor blocking drugs are administered concomitantly with TWYNSTA, patients should be carefully monitored since blood pressure lowering effect of beta-blockers may be augmented by amlodipine's reduction in peripheral vascular resistance. |
| Sildenafil | CT | A single 100 mg dose of sildenafil (Viagra) in subjects with essential hypertension had no effect on AUC or | Monitoring blood pressure is recommended and antihypertensive therapy may |

| Amlodipine | Source of evidence | Effect | Clinical comment |
|---|---------------------------|---|--|
| | | Cmax of amlodipine. When sildenafil (100 mg) was co-administered with amlodipine, 5 or 10 mg in hypertensive patients, the mean additional reduction of supine blood pressure was 8 mm Hg systolic and 7 mm Hg diastolic. | be adjusted. |
| Atorvastatin | CT | In healthy volunteers, co-administration of multiple 10 mg doses of amlodipine with 80 mg of atorvastatin resulted in no clinical significant change in the AUC (average of 18% increase) or Cmax or Tmax of atorvastatin. | Close monitoring is required. |
| Simvastatin | CT | Co-administration of multiple doses of 10 mg of amlodipine with simvastatin 80 mg resulted in a 77% increase in simvastatin exposure compared to simvastatin exposure when used alone. | Limit the dose of simvastatin in patients on amlodipine to 20 mg daily. |
| Immunosuppressants | | Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. | Frequent monitoring of trough blood levels of cyclosporine and tacrolimus and dose adjustment when appropriate is recommended. |
| Cyclosporine | CT | No drug interaction studies have been conducted with cyclosporine and amlodipine in healthy volunteers or other populations with the exception of renal transplant patients. A prospective study in hypertensive renal transplant patients (N=11) showed on an average of 40% increase in trough cyclosporine levels when concomitantly treated with amlodipine. | |
| Tacrolimus | C | There is a risk of increased tacrolimus blood levels when co-administered with amlodipine. | |
| Mechanistic Target of Rapamycin (mTOR) Inhibitors | CT T | mTOR inhibitors such as sirolimus, temsirolimus, and everolimus are CYP3A substrates. Amlodipine is a weak CYP3A inhibitor. With concomitant use | Caution is advised |

| Amlodipine | Source of evidence | Effect | Clinical comment |
|------------|--------------------|---|--|
| | | of mTOR inhibitors, amlodipine may increase exposure of mTOR inhibitors. | |
| Dantrolene | T | In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. | Due to risk of hyperkalemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia. |

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

Amlodipine has a low (rate of first-pass) hepatic clearance and consequent high bioavailability, and thus, may be expected to have a low potential for clinically relevant effects associated with elevation of amlodipine plasma levels when used concomitantly with drugs that compete for or inhibit the cytochrome P450 system (e.g., benzodiazepines, flecainide, imipramine, propafenone, theophylline).

9.5 Drug-Food Interactions

When telmisartan is taken with food, the reduction in the area under the plasma concentration-time curve (AUC) of telmisartan varies from approximately 6% (40 mg dose) to approximately 19% (160 mg dose). By 3 hours after administration plasma concentrations are similar whether telmisartan is taken fasting or with food (see [10.3 Pharmacokinetics, Distribution](#)).

Administration of amlodipine with grapefruit or grapefruit juice is not recommended since bioavailability may be increased in certain patients resulting in increased blood pressure lowering effects.

Telmisartan/Amlodipine fixed-dose combination:

A bioavailability study was conducted to determine the effect of food on the pharmacokinetics of telmisartan and amlodipine when they are combined together in a fixed dose combination tablet. The bioavailability and pharmacokinetics of the highest dose strength of the fixed dose combination to be marketed (T80/A10) were investigated in the fasting state in 39 subjects (20 men and 19 women) and then after administration of a standardised high fat, high caloric meal, for the purpose of comparison. There was an approximately 25% reduction in the concentration of telmisartan after a high-fat meal, compared to the concentration in the fasting state. The telmisartan concentration reduction was greater in women than men.

Under the same conditions, the amlodipine concentration was minimally increased after the high-fat meal. The terminal half-lives of both telmisartan and amlodipine were unchanged, irrespective of the fasting or high-fat fed state. The results of this study are more conclusive for amlodipine than telmisartan, as the pre-specified confidence interval for the assessment of telmisartan bioavailability was exceeded. Therefore, a lack of food effect on pharmacokinetics can be concluded for amlodipine but not for telmisartan.

9.6 Drug-Herb Interactions

St-John's Wort is an inducer of CYP3A4. The concomitant use of CYP3A4 inducers may give a lower plasma concentration of amlodipine which in turn can result in decreased blood pressure lowering effects. Amlodipine should be used with caution together with CYP3A4 inducers and dose adjustment may be necessary to maintain efficacy. Hence, monitoring of therapy is required.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Telmisartan

Telmisartan is an orally active angiotensin II AT₁ receptor blocker. By selectively blocking the binding of angiotensin II to the AT₁ receptors telmisartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II. Telmisartan does not exhibit any partial agonist activity at the AT₁ receptors and has essentially no affinity for the AT₂ receptors. AT₂ receptors have been found in many tissues, but to date they have not been associated with cardiovascular homeostasis. In vitro binding studies indicate that telmisartan has no relevant affinity for other receptors nor does it inhibit human plasma renin.

Telmisartan does not inhibit angiotensin converting enzyme, also known as kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin, nor does it affect renin or other hormone receptors or ion channels involved in cardiovascular regulation of blood pressure and sodium homeostasis.

In hypertensive patients blockade of angiotensin II AT₁ receptors results in two to three fold increase in plasma renin and angiotensin II plasma concentrations. Long term effects of increased AT₂ receptor stimulation by angiotensin II are unknown.

Amlodipine

Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker

or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac muscle and vascular smooth muscle.

The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, leading to reductions in peripheral vascular resistance and in blood pressure. Experimental data indicate that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. Amlodipine is relatively vessel-selective, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells.

In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action of amlodipine, acute hypotension was not observed.

10.2 Pharmacodynamics

Pharmacotherapeutic group: angiotensin II blockers, plain (telmisartan), combinations with dihydropyridine derivatives (amlodipine), ATC Code: C09DB04.

TWYNSTA combines two antihypertensive compounds with different mechanisms to control blood pressure in patients with essential hypertension: an angiotensin II receptor blocker, telmisartan, and a dihydropyridinic calcium channel blocker, amlodipine.

The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.

TWYNSTA once daily produces effective and consistent reductions in blood pressure across the 24-hour therapeutic dose range.

Diabetic Patients: Multiple exploratory post hoc analyses were carried out on the three cardiovascular (CV) outcome trials (ONTARGET, TRANSCEND and PRoFESS). In TRANSCEND and PRoFESS, an increased risk of unexpected CV death was seen with telmisartan versus placebo in diabetics without previously diagnosed coronary artery disease (CAD) but not in those with a documented history of CAD. No such increased risk was demonstrated in ONTARGET for telmisartan versus ramipril in diabetes patients without previously diagnosed CAD.

These findings in diabetics with added cardiovascular risk, could be related to a pre-existing but asymptomatic or silent CAD. Diabetics with undiagnosed and therefore untreated CAD may be at increased risk when lowering blood pressure too far, e.g. when initiating antihypertensive therapy, due to a further reduction of perfusion in an already narrowed coronary artery.

Telmisartan

In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by about 90% at peak with approximately 40% inhibition persisting for 24 hours.

In hypertensive patients with normal renal function, no clinically significant effects on renal plasma flow, filtration fraction, or glomerular filtration rate were observed. In multiple dose studies in hypertensive patients, telmisartan had no adverse effect on renal function as measured by serum creatinine or blood urea nitrogen.

The antihypertensive effects of telmisartan were demonstrated in six placebo-controlled clinical trials, in a total of 1773 patients, 1031 of whom were treated with telmisartan. Upon initiation of antihypertensive treatment with telmisartan, blood pressure was reduced after the first dose and there was a gradual increase in the antihypertensive effect during continued treatment for up to 12 weeks, with most of the increase occurring during the first month. Onset of antihypertensive activity occurs within 3 hours after administration of a single oral dose. The antihypertensive effect of once daily administration of telmisartan is maintained for the full 24-hour dose interval. The magnitude of blood pressure reduction from baseline, after placebo subtraction, was on average (SBP/DBP) -11.3/-7.3 mmHg for telmisartan 40 mg once daily, and -13.7/-8.1 mmHg for telmisartan 80 mg once daily. Upon abrupt cessation of treatment with telmisartan, blood pressure gradually returned to baseline values over a period of several days. During long term studies (without placebo control) the effect of telmisartan appeared to be maintained for up to at least one year.

For those patients treated with telmisartan 80 mg once daily who required additional blood pressure reduction, addition of a low dose of hydrochlorothiazide (12.5 mg) resulted in incremental blood pressure reductions of -9.4/-7.0 mmHg.

The antihypertensive effect of once-daily telmisartan (40-80 mg) was similar to that of once-daily amlodipine (5-10 mg), atenolol (50-100 mg), enalapril (5-20 mg) and lisinopril (10-40 mg).

There was essentially no change in heart rate in telmisartan-treated patients in controlled trials.

In clinical trials with post-dose in-clinic monitoring no excessive blood pressure lowering peak effect was observed even after the first dose, and the incidence of symptomatic orthostasis was very low (0.04%). With automated ambulatory blood pressure monitoring, the 24-hour trough-to-peak ratio for telmisartan was determined to be at least 80% for both systolic and diastolic blood pressure.

The antihypertensive effect of telmisartan is not influenced by patient age, weight or body mass index.

Amlodipine

In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.

Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.

10.3 Pharmacokinetics

Table 7: Summary of telmisartan pharmacokinetic parameters (arithmetic means, CV%) in healthy volunteers, male, range: 20-47 years

| Administration | C _{max} (ng/mL) | T _{max} (h) | t _½ (h) | AUC _{0-∞} (ng h/mL) | CL (mL/min) | Vz/f (L) |
|----------------------------|--------------------------|----------------------|--------------------|------------------------------|-------------|-------------|
| 40 mg, single dose, tablet | 32.1 (44.9) | 1.75 (27.9) | 19.6 (36.8) | 360 (61.5) | 2670 (61.4) | 4490 (84.9) |

| Administration | C _{max} (ng/mL) | T _{max} * (h) | t _½ (h) | AUC _{0-∞} (ng h/mL) | CL (mL/min) | Vz/f (L) |
|----------------------------|--------------------------|------------------------|--------------------|------------------------------|--------------|--------------|
| 80 mg, single dose, tablet | 245 (69.4) | 1.00 (0.5-2.00) | 27.29 (37.28) | 1280 (91.71) | 1766 (68.68) | 3890 (95.49) |

* Median

Pharmacokinetics of the co-administration of telmisartan and amlodipine as a free combination, were evaluated in two studies:

In one study pharmacokinetics of repeated oral doses of 10 mg amlodipine daily and of 10 mg amlodipine and 120 mg telmisartan daily were evaluated in a cross-over randomised open label study in healthy subjects. For this study, the reference treatment was amlodipine, 10 mg a day. Amlodipine 10 mg, or amlodipine 10 mg administered with telmisartan monotherapy were administered for 9 days, with a 13 to 15 day washout period between the two treatment periods.

The geometric mean ratios and 90% confidence intervals of AUC_{τ,ss} and C_{max,ss} for amlodipine with (T) and without telmisartan (R) were as follows:

| Parameter N=36 | T/R ratio [%] | 90% CI | |
|---------------------|------------------|--------------------|--------------------|
| | | lower limit [%] | upper limit [%] |
| AUC _{τ,ss} | 106 | 98 | 116 |
| C _{max,ss} | 106 | 97 | 114 |

The confidence interval for the $AUC_{T,SS}$ ratio was within the prespecified bioequivalence limits of 80 – 125%, and the confidence interval for the $C_{max,SS}$ ratio was within the prespecified bioequivalence limits of 80-125%. Based on the primary endpoints, $AUC_{T,SS}$ and $C_{max,SS}$, amlodipine bioequivalence was demonstrated and it was concluded that there was no drug interaction between amlodipine and telmisartan.

Pharmacokinetics of repeated oral doses of telmisartan 80 mg at steady state alone and in combination with repeated oral doses of amlodipine 10 mg were studied at steady state in a two-way crossover, open, randomised design study. The reference treatment was telmisartan, 80 mg a day, administered alone, for 9 days. The test treatment was telmisartan, 80 mg a day, co-administered with amlodipine, 10 mg a day, for 9 additional days. There was a 15 day washout between test periods.

The geometric mean ratios and 90% confidence intervals of $AUC_{T,SS}$ and $C_{max,SS}$ for telmisartan with (T) and without amlodipine (R) were as follows:

| Parameter N=36 | T/R ratio [%] | 90% CI | |
|-------------------|------------------|--------------------|--------------------|
| | | lower limit [%] | upper limit [%] |
| $AUC_{T,SS}$ | 98 | 89 | 107 |
| $C_{max,SS}$ | 89 | 76 | 104 |

The confidence interval for the $AUC_{T,SS}$ ratio was within the prespecified bioequivalence limits of 80 – 125%, and the confidence interval for the $C_{max,SS}$ ratio was within the prespecified bioequivalence limits of 75 – 133%. The latter were defined to be wider than for $AUC_{T,SS}$ because telmisartan is known to be a highly variable drug with respect to intrasubject variability of C_{max} , but also has a wide therapeutic window. It was concluded that there is no clinically significant change in systemic exposure to telmisartan 80 mg on coadministration of amlodipine 10 mg after dosing both medications to steady state and that there is no relevant drug-drug interaction with regard to the effect of amlodipine on telmisartan.

Pharmacokinetics of the Fixed Dose Combination

The rate and extent of absorption of TWYNSTA are equivalent to the bioavailability of telmisartan and amlodipine when administered as individual tablets.

Pharmacokinetic of the Single Components

Absorption:

Telmisartan: Following oral administration, telmisartan is well absorbed, with a mean absolute bioavailability of about 50%. Mean peak concentrations of telmisartan are reached in 0.5-1

hour after dosing.

The pharmacokinetic profile is characterized by greater than proportional increases of plasma concentrations (C_{max} and AUC) with increasing doses greater than 40 mg. Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours, and does not accumulate in plasma upon repeated once-daily dosing.

Amlodipine: After oral administration of therapeutic doses of amlodipine alone, peak plasma concentrations of amlodipine are reached in 6–12 hours. Absolute bioavailability has been calculated as between 64% and 80%. Amlodipine bioavailability is unaffected by food ingestion.

Distribution:

Telmisartan: Telmisartan is >99.5% bound to plasma protein, mainly albumin and alpha1-acid glycoprotein. Plasma protein binding is constant over the concentration range achieved with therapeutic doses. The volume of distribution for telmisartan is approximately 500 liters, indicating additional tissue binding sites.

When telmisartan is taken with food, the reduction in the area under the plasma concentration-time curve (AUC) of telmisartan varies from approximately 6% (40 mg) to approximately 19% (160 mg), and the reduction in C_{max} varies from approximately 26% (40 mg) to 56% (160 mg). However, three hours after administration, plasma concentrations are similar whether telmisartan is taken with or without food. The small reduction in AUC is not expected to cause a reduction in the therapeutic efficacy (see [9 DRUG INTERACTIONS, 9.5 Drug-Food Interactions](#)).

Amlodipine: The volume of distribution of amlodipine is approximately 21 L/kg. In vitro studies with amlodipine have shown that approximately 97.5% of circulating drug is bound to plasma proteins in hypertensive patients.

Metabolism:

Telmisartan: Telmisartan is metabolized by conjugation with glucuronic acid to form an acylglucuronide of telmisartan. This glucuronide is the only metabolite which has been identified in human plasma and urine. Following both oral dosing and intravenous administration of radiolabeled telmisartan, the parent compound represented approximately 85% and the glucuronide approximately 11% of total radioactivity in plasma. No pharmacological activity has been shown for the glucuronide conjugate.

The CYP 450 isoenzymes are not responsible for telmisartan metabolism.

Amlodipine: Amlodipine is extensively (approximately 90%) metabolised by the liver to inactive metabolites.

Elimination:

Telmisartan: Total plasma clearance of telmisartan is > 800 mL/min. Half-life and total clearance appear to be independent of dose. Biliary excretion is the main route of elimination of telmisartan and its metabolite. Following intravenous and oral administration of C¹⁴ labelled telmisartan 0.91% and 0.49% of administered dose were found in the urine as glucuronide, respectively. Most of the oral and intravenous dose, >97%, was excreted in feces as the parent compound.

Amlodipine: Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of approximately 30 to 50 hours. Steady-state plasma levels are reached after continuous administration for 7–8 days. Ten per cent of original amlodipine and 60% of amlodipine metabolites are excreted in urine.

Special Populations and Conditions

- **Pediatrics (age below 18 years)**: Telmisartan pharmacokinetics have not been investigated in patients <18 years of age.
- **Geriatrics**
Telmisartan: The pharmacokinetics of telmisartan do not differ between the geriatric and those younger than 65 years.
Amlodipine: Time to peak plasma amlodipine concentrations is similar in young and elderly patients. In elderly patients, amlodipine clearance tends to decline, causing increases in the area under the curve (AUC) of about 60% and elimination half-life.
- **Sex** Plasma concentrations of telmisartan are generally 2-3 fold higher in females than in males. No dosage adjustment is necessary. Women have a lower telmisartan clearance and have a greater systolic blood pressure response at trough than men.
- **Genetic Polymorphism: *Telmisartan***: No studies were conducted to evaluate the influence of genetic polymorphisms on the pharmacokinetics or pharmacodynamics of telmisartan.
- **Ethnic Origin**: The effectiveness of TWYNSTA in black patients (usually a low-renin population) was not significantly different than observed in other patients.

However, in the Pivotal Study, since the majority of patients within each treatment group were non-black comparison across race is difficult. Baseline values were generally similar for the two race categories. In the combination treatment groups, diastolic blood pressure reductions observed with the combination therapy were numerically smaller in blacks than non-blacks, with the exception of T40+A10 treatment group. This finding is not unexpected in this population that is generally recognized as having low renin levels. However, based on the achieved blood pressure

reductions, the T+A combination can be considered effective in black patients as well.

- **Hepatic Insufficiency *Telmisartan*:** In patients with hepatic insufficiency, plasma concentrations of telmisartan are increased, and absolute bioavailability approaches 100%. The maximum dose in these patients is 40 mg.

Amlodipine: Patients with hepatic insufficiency have decreased clearance of amlodipine with resulting increase of approximately 40–60% in AUC. Dosage requirements have not been established in patients with impaired hepatic function. When amlodipine is used in these patients the dosage should be carefully and gradually adjusted depending on patients tolerance and response. A lower starting dose should be considered.

- **Renal Insufficiency *Telmisartan*:** Renal excretion of telmisartan is negligible. No dosage adjustment is necessary in patients with renal insufficiency. In patients on haemodialysis both C_{max} and AUC of telmisartan were markedly reduced as compared to healthy volunteers. Telmisartan is not removed by haemodialysis.

Amlodipine: The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. The recommended initial dose is 5 mg once daily. If required, increasing the dose should be done gradually and with caution.

11 STORAGE, STABILITY AND DISPOSAL

Store at 15-30°C.

Store in the original package in order to protect from light and moisture.

Due to the hygroscopic property of the tablets, they should be taken out of the sealed blister shortly before administration.

12 SPECIAL HANDLING INSTRUCTIONS

There are no special handling instructions.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: telmisartan

Chemical name: [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'-propyl[2,6'- bi-1H-benzimidazol]-1'-yl)methyl]

Molecular formula and molecular mass: C₃₃H₃₀N₄O₂, 514.63

Structural formula:



Physicochemical properties:

Description:

Telmisartan is a white to off-white, odorless crystalline powder. It is practically insoluble in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except HCl) and soluble in strong base.

Polymorphism:

Exhibits two different polymorphic modifications, Form A (thermodynamically more stable) and form B, and a third pseudo polymorphic form.

Melting Point:

269 ± 1°C (polymorphic Form A)

183 ± 1°C (polymorphic Form B)


Drug Substance

Proper name: amlodipine besylate

Chemical name: 3-Ethyl 5-methyl (4RS)-2[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate

Molecular formula and molecular mass: C₂₀H₂₅ClN₂O₅.C₆H₆O₃S, 567.1

Structural formula:



Physicochemical properties:

Physical Form:

Amlodipine besylate is a white crystalline substance.

Solubility:

Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol, M.P.= 203°C with decomposition.

pKa = 9.02 at 23.5°C.

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

INDICATION 1

Treatment of mild to moderate essential hypertension for whom combination therapy with telmisartan and amlodipine is appropriate.

Table 9: Summary of patient demographics for clinical trials in treatment of mild to moderate essential hypertension for whom combination therapy is appropriate

| Study # | Study design | Dosage, route of administration and duration | Study subjects (n) | Mean age (Range) | Sex |
|-----------|--|--|--------------------|------------------|--------------------------|
| 1235-0001 | randomised, double-blind, placebo-controlled, parallel group factorial study | oral | 1461 | 53.1 years | 50.4% male, 49.6% female |

Study # 1235-0001

In a single 8-week multicenter, randomised, double-blind, placebo-controlled, parallel group factorial study, 1461 patients with mean seated diastolic blood pressure ≥ 95 and < 119 mmHg in which subjects were treated with combination doses of TWYNSTA (telmisartan [T] and amlodipine [A]) or its monotherapy components, including T/A doses of T40+A5, T40+A10,

T80+A5, and T80+A10 mg), the combination treatments showed significant dose related reductions in systolic and diastolic blood pressure from baseline values. Limited data was available in subjects with severe hypertension.

Study demographics and trial design

Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%) black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%) of patients ≥65 years old. The majority of patients had a duration of hypertension >5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), >5 years: 806 (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed antihypertensive medication, 531 (36.3%) previously treated with antihypertensive monotherapy, and 623 (42.6%) previously treated with combination therapy of ≥2 antihypertensive medications. The overall mean body mass index (BMI) was 31.3 kg/m² with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal impairment.

Study Results

The primary endpoint of this study was the change from baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after 8 weeks of treatment.

Treatment with each combination dose of TWYNSTA resulted in significantly greater diastolic and systolic blood pressure reductions and higher control rates compared to the respective monotherapy components. The telmisartan/amlodipine combinations showed dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy:

Table 10: The Effect of Telmisartan/Amlodipine Combination in Reduction of Systolic/Diastolic Blood Pressure versus Telmisartan Monotherapy or Amlodipine Monotherapy

| | Telmisartan/Amlodipine Dose | | | | | | | |
|---------------------|-----------------------------|----------|-----------|-----------|---------|---------|--------|-------|
| mg | 40/5 mg* | 80/5 mg* | 40/10 mg* | 80/10 mg* | 40/0 mg | 80/0 mg | 0/5 mg | 0/10 |
| Systolic BP (mmHg) | -21.8 | -22.1 | -24.7 | -26.4 | -14.6 | -14.3 | -15.4 | -20.7 |
| Diastolic BP (mmHg) | -16.5 | -18.2 | -20.2 | -20.1 | -13.4 | -14.0 | -13.4 | -17.1 |

* p < 0.05 versus telmisartan monotherapy or amlodipine monotherapy

The greatest overall reduction in blood pressure was observed with telmisartan 80 mg plus amlodipine 10 mg combination (mean reduction in SBP/DBP; -26.4/-20.1 mmHg; p < 0.05 vs. both monotherapies).

The proportions of patients reaching DBP <90 mmHg with a telmisartan/amlodipine combination were:

71.6% with 40/5 mg,

74.8% with 80/5 mg,

82.1% with 40/10 mg, and

85.3% with 80/10 mg.

A subset of 1050 patients in the factorial design study had moderate to severe hypertension (DBP \geq 100 mmHg). In these patients, the observed mean changes in SBP/DBP with a combination therapy containing amlodipine 5 mg (-22.2/-17.2 mmHg with 40/5 mg; -22.5/-19.1 mmHg with 80/5 mg) were comparable to or greater than those seen with amlodipine 10 mg (-21.0/-17.6 mmHg). Additionally, combination therapy showed notably lower edema rates (1.4% with 40/5 mg; 0.5% with 80/5 mg; 17.6% with amlodipine 10 mg).

The majority of the antihypertensive effect was attained within 2 weeks after initiation of therapy.

Automated ambulatory blood pressure monitoring (ABPM) performed in a subset of 562 patients confirmed the results seen with in-clinic SBP and DBP reductions consistently over the entire 24-hours dosing period.

There was a significant difference in the change from baseline in seated trough cuff DBP among dosages of telmisartan (T: $p < 0.0001$) and among dosages of amlodipine (A: $p < 0.0001$), with no significant ($p = 0.1777$) T-by-A interaction when excluding placebo patients, concluding that combination therapy with T+A is superior to either monotherapy in lowering seated trough cuff DBP in patients with Stage I or II hypertension.

The antihypertensive effect of TWYNSTA was similar irrespective of age and gender, and was similar in patients with and without diabetes.

TWYNSTA has not been studied in any patient population other than essential hypertension.

14.2 Comparative Bioavailability Studies

Bioequivalence was demonstrated between TWYNSTA (telmisartan/ amlodipine besylate) fixed dose combination tablets and the co-administration of the mono-component Canadian products MICARDIS (telmisartan) and NORVASC (amlodipine besylate) tablets based on comparative bioavailability data from open label, single-dose, two-period crossover studies conducted in healthy volunteers, under fasted conditions. The comparative bioavailability data is summarized below:

Table 11: Results for Telmisartan

| Telmisartan (1 x 80 mg as either TWYNSTA or MICARDIS) | | | | |
|---|------------|------------------------|----------------------------|-------------------------|
| Geometric Mean | | | | |
| Arithmetic Mean (CV%) | | | | |
| Parameter | Test* | Reference [†] | % Ratio of Geometric Means | 90% Confidence Interval |
| AUC ₀₋₇₂ (ng.h/mL) | 1115 (79%) | 1128 (88%) | 103 | 98 - 108 |
| | 922 | 898 | | |
| C _{max} (ng/mL) | 281 (110%) | 278 (121%) | 109 | 98 - 120 |
| | 205 | 188 | | |

* TWYNSTA (telmisartan/amlodipine besylate) 80/10 mg combination tablet, by Boehringer Ingelheim (Canada) Ltd/Ltee.

[†] MICARDIS (telmisartan) 80 mg tablet, by Boehringer Ingelheim (Canada) Ltd/Ltee.

Table 12: Results for Amlodipine

| Amlodipine (1 x 10 mg as either TWYNSTA or NORVASC) | | | | |
|---|-------------|------------------------|----------------------------|-------------------------|
| Geometric Mean | | | | |
| Arithmetic Mean (CV%) | | | | |
| Parameter | Test* | Reference [€] | % Ratio of Geometric Means | 90% Confidence Interval |
| AUC ₀₋₇₂ (ng.h/mL) | 263.4 (23%) | 275.6 (24%) | 95 | 92 - 98 |
| | 255 | 269 | | |
| C _{max} (ng/mL) | 6.81 (20%) | 7.25 (22%) | 94 | 91 - 98 |
| | 6.6 | 7.0 | | |

* TWYNSTA (telmisartan/amlodipine besylate) 80/10 mg combination tablet, by Boehringer Ingelheim (Canada) Ltd/Ltee.

[€] NORVASC (amlodipine besylate) 10 mg tablet, by Pfizer Canada Inc.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

Since the non-clinical toxicity profiles of telmisartan and amlodipine are not overlapping, no exacerbation of toxicity was expected for the combination.

This has been shown in a subchronic (13-week) toxicology study in rats, in which dose levels of 3.2/0.8, 10/2.5 and 40/10 mg/kg of telmisartan and amlodipine were tested. In this study, no additive or greater than additive adverse effects of amlodipine and telmisartan in combination

as well as no change of the toxicity profile with regard to target organs were observed.

With respect to telmisartan/amlodipine (TWYNSTA), separate reproductive toxicity studies assessing the potential effects of telmisartan and amlodipine on male or female fertility when both compounds are given in combination, have not been conducted.

Preclinical data available for the components of this fixed dose combination are reported below.

Telmisartan

General Toxicology:

Acute Toxicity:

In acute oral toxicity studies no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest oral dose tested. The i.v. LD₅₀ in rats was 150-200 mg/kg in males and 200-250 mg/kg in females.

Chronic Toxicity

Chronic oral toxicity of telmisartan was evaluated in studies following administration of doses ≤ 500 mg/kg for ≤ 26 weeks in rats, and ≤ 1 year in dogs. Chronic intravenous toxicity was evaluated in studies of ≤ 4 weeks at doses ≤ 20 mg/kg in rats and ≤ 50 mg/kg in dogs.

Repeated dose administration of telmisartan resulted in marked and long lasting hypotension, hyperplasia of juxtaglomerular apparatus and lesions of the gastrointestinal tract. Further effects were reduced body weight gain, heart weight and red blood cell indices, increased potassium and AST and ALT, the latter in the absence of morphological evidence of toxicity. No effect doses were not identified for decreased erythroid indices, increased BUN and juxtaglomerular hypertrophy/hyperplasia in rats and dogs.

Gastrointestinal Tract

Gastric and/or duodenal mucosal erosions and ulcers were seen in rats given ≥4 mg/kg orally or ≥2 mg/kg i.v. and in dogs given ≥40 mg/kg orally. Most lesions were small, focal or multifocal in distribution and limited to the mucosa and submucosa. Ulcers and erosions healed rapidly after drug withdrawal.

Urinary Tract and Electrolytes

Hypertrophy of the juxtaglomerular apparatus and increased granularity of renin-producing cells of the juxtaglomerular apparatus, afferent arterioles and interlobular arteries of the kidney were observed in rats at doses of ≥ 1 mg/kg and in dogs at ≥ 5 mg/kg. In rats and dogs subjected to long term treatment with telmisartan, plasma renin activity returned to normal

levels after 26 to 52 weeks of treatment. Reversible slight to mild increases in serum potassium levels occurred in rats at oral doses of ≥ 4 mg/kg. In dogs, non-progressive increases in serum potassium levels were noted at 50 and 500 mg/kg in the 52 week oral study. Minimal to mild, reversible increases in blood urea nitrogen and creatinine were evident at oral doses of ≥ 4 mg/kg in rats and ≥ 5 mg/kg in dogs.

Haematology

Slight to mild reversible reductions of red blood cell count, hematocrit, and/or haemoglobin were observed after repeated oral dosing with telmisartan ≥ 50 mg/kg in the rat and ≥ 5 mg/kg in the dog.

Carcinogenicity:

The carcinogenic potential of telmisartan was assessed in 2-year feeding studies in mice at doses of 10, 100 and 1000 mg/kg and in rats at 3, 15 and 100 mg/kg. Drug administration did not affect survival time in either study and also tumour mortality was not increased. Incidence and time to appearance of palpable masses showed no treatment influence in mice and rats. No increases were observed in overall tumour incidence, incidence of benign and malignant tumours or tumour multiplicity.

Genotoxicity:

Mutagenicity

Telmisartan was not mutagenic at a concentration range of 10 to 2500 $\mu\text{g}/\text{plate}$ in the bacterial reverse mutation assay, with or without metabolic activation. No potential for chromosomal damage was found in the mouse micronucleus test at a dose range of 250 to 1000 mg/kg. No forward mutations at the HPRT locus in V79 cells were induced at a concentration range of 10 to 100 $\mu\text{g}/\text{ml}$, with or without metabolic activation. No chromosomal aberrations were induced in human peripheral lymphocytes *in vitro* at concentrations ≤ 100 $\mu\text{g}/\text{ml}$ without metabolic activation and concentrations ≤ 200 $\mu\text{g}/\text{ml}$ with metabolic activation.

Reproductive and Developmental Toxicology:

Reproduction

In studies on fertility and reproductive performance in male and female rats no effect on mating performance, reproductive organs, or fertility in either sex, or on litter parameters was observed with telmisartan doses of 5-100 mg/kg. No teratogenic or embryotoxic potential in rats was observed at doses up to 50 mg/kg administered from day 7 through day 16 of pregnancy. However, at toxic dose levels, non-clinical studies indicated some hazardous potential of telmisartan to fetal development (increased number of late resorptions in rabbits) and to the postnatal development of the offspring: lower body weight, delayed eye opening, and higher mortality.

Telmisartan was detectable in the placenta, fetus and amniotic fluid of rats after single oral

doses of 1 mg/kg.

Amlodipine

Carcinogenicity:

Carcinogenesis, mutagenesis

Rats and mice treated with amlodipine maleate in the diet for up to two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 amlodipine mg/kg/day, showed no evidence of a carcinogenic effect of the drug. For the mouse, the highest dose was, on a mg/m² basis, similar to the maximum recommended human dose of 10 mg amlodipine/day*. For the rat, the highest dose was, on a mg/m² basis, about twice the maximum recommended human dose*.

Mutagenicity studies revealed no drug-related effects at either the gene or chromosome levels.

*Based on patient weight of 50 kg

Reproductive and Developmental Toxicology:

Reproductive toxicology

No evidence of teratogenicity or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses up to 10 mg amlodipine/kg/day (approximately 10 and 20 times the maximum recommended human dose based on body surface area, respectively) during their respective periods of major organogenesis. However for rats, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold) in rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose.

Impairment of fertility

There was no effect on the fertility of rats treated orally with amlodipine maleate (males for 64 days and females for 14 days prior to mating) at doses ≤ 10 mg amlodipine/kg/day (about 8 times the maximum recommended human dose of 10 mg/day on a mg/m² basis, for a 50 kg human).

In another rat study in which male rats were treated with amlodipine besylate for 30 days at a dose comparable with the human dose based on mg/kg decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr**TWYNSTA**[®]

Telmisartan/Amlodipine (as Amlodipine Besylate) Tablets

Read this carefully before you start taking **TWYNSTA** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **TWYNSTA**.

Serious Warnings and Precautions

- **TWYNSTA should not be used during pregnancy. Taking TWYNSTA during pregnancy can cause injury or even death to your baby.**
- **If you discover that you are pregnant while taking TWYNSTA, stop the medication and talk to your healthcare professional as soon as possible.**

What is TWYNSTA used for?

- TWYNSTA is used in adults to treat mild to moderate **high blood pressure**.

How does TWYNSTA work?

TWYNSTA contains 2 medicines, telmisartan and amlodipine. They work together to control your blood pressure:

- Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an ARB because its medicinal ingredient ends in “**-SARTAN**”.
- Amlodipine is a calcium channel blocker.

This medicine does not cure high blood pressure. It helps to control it. Therefore, it is important to continue taking TWYNSTA regularly even if you feel fine. Do not stop taking your medicine without talking to your healthcare professional.

What are the ingredients in TWYNSTA?

Medicinal ingredients: telmisartan and amlodipine (as amlodipine besylate)

Non-medicinal ingredients: colloidal anhydrous silica, FD&C blue No 1 aluminium lake, ferric oxide black, ferric oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol

TWYNSTA comes in the following dosage forms:

Tablets: 40 mg / 5 mg, 40 mg / 10 mg, 80 mg / 5 mg, 80 mg / 10 mg

Do not use TWYNSTA if you:

- are allergic to:
 - telmisartan
 - amlodipine
 - medicines of the dihydropyridine type (a type of calcium channel blocker)
 - other ARBs
 - any non-medicinal ingredient in TWYNSTA (see **What are the ingredients in TWYNSTA?**)
- have had an allergic reaction (angioedema) with swelling of the hands, feet, or ankles, face, lips, tongue, throat, or sudden difficulty breathing or swallowing, to any ARB
- are pregnant or planning to become pregnant. Taking TWYNSTA during pregnancy can cause injury and even death to your baby.
- are breastfeeding. TWYNSTA passes into breast milk.
- have been diagnosed with hereditary fructose intolerance, a rare genetic disorder where you cannot break down fructose. TWYNSTA 80 mg / 5 mg and 80 mg / 10 mg tablets contain 337.28 mg of a similar type of sugar called sorbitol.
- have severe liver problems or problems with drainage of the bile from the liver and gallbladder (biliary obstruction)
- have a serious heart problem, such as:
 - cardiac shock, where your heart cannot pump enough blood to your brain and organs
 - aortic stenosis, a narrowing of the aortic heart valve
 - problems with the heart muscle (hypertrophic cardiomyopathy)
 - unstable heart failure after a heart attack
- are already taking a blood pressure-lowering medicine that contains aliskiren and you have diabetes or kidney disease
- have very low blood pressure

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take TWYNSTA. Talk about any health conditions or problems you may have, including if you:

- are allergic to any medicine used to lower blood pressure including angiotensin converting enzyme (ACE) inhibitors
- have a history of allergic reactions (angioedema)
- have a condition in which your body releases too much of the hormone aldosterone in your blood (primary aldosteronism)
- are taking any of the following:
 - other blood pressure lowering medicines, such as:
 - aliskiren
 - an angiotensin-converting-enzyme inhibitor (ACEI)

- beta blockers (i.e. acebutolol, atenolol, metoprolol, nadolol). Do NOT stop taking your beta-blocker without talking to your healthcare professional as this can cause serious side effects.
 - medicines used to treat bacterial or fungal infections, such as:
 - macrolides, e.g., clarithromycin
 - azole antifungals, e.g., ketoconazole
 - ritonavir, used to treat HIV infection
- have heart problems, such as:
 - chest pain (angina)
 - narrowing of an artery or heart valve
 - heart or blood vessel disease
 - heart failure
 - recent heart attack
- have kidney problems, such as:
 - a narrowing of the blood vessels to one or both kidneys (renal artery stenosis)
 - a kidney transplant
 - you are on dialysis
- have diabetes
- have liver problems
- are dehydrated or suffer from excessive vomiting, diarrhea, or sweating
- are on a low-salt diet
- are at risk for developing high levels of potassium in your blood (hyperkalemia). This can be serious and can happen if you are taking:
 - a salt substitute that contains potassium
 - potassium supplements
 - a kind of “water pill” (potassium sparing) that makes your body hold on to potassium
 - other medicines that may increase potassium in your blood, such as the blood thinner heparin
- are 65 years of age or older. You may be more at risk of experiencing side effects.

Other warnings you should know about:

TWYNSTA can cause serious side effects, including:

- **Allergic reactions / Angioedema:** Allergic reactions (angioedema) causing swelling of tissues under the skin, sometimes affecting the face and throat, have happened in people taking TWYNSTA. These allergic reactions may happen at any time during treatment with TWYNSTA and can be life threatening. Very rarely, cases have been fatal. If you experience an allergic reaction, stop taking TWYNSTA and get immediate medical help.
- **Hypotension (low blood pressure):** You may feel dizzy or light-headed:
 - in the first few days after you start taking TWYNSTA
 - when your dose is increased

- when you exercise
- when the weather is hot

You should lie down if this happens. If you faint, stop taking TWYNSTA and talk to your healthcare professional.

- **Blood disorders:** TWYNSTA, may cause:
 - neutropenia / agranulocytosis (decrease in white blood cells)
 - thrombocytopenia (low blood platelets)
 - anaemia (low red blood cells)

See the **Serious side effects and what to do about them** table, below, for more information on these and other serious side effects.

Surgery: Before surgery or general anaesthetic (even at the dentist's office), tell your healthcare professional that you are taking TWYNSTA. You may experience a sudden fall in blood pressure when you are under general anaesthesia.

Increased sensitivity of the skin to sun: Your skin may become sensitive to the sun while you are taking TWYNSTA. Limit your exposure to the sun and to indoor tanning. Always use sunscreen (SPF-30 or higher) and wear protective clothing when going outside. Talk to your healthcare professional if your skin gets itchy and red after being exposed to sunlight.

Driving and using machines: Before you perform tasks which may require special attention, wait until you know how you respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur after the first dose and when the dose is increased.

Blood tests: Your healthcare professional may do blood tests before you take TWYNSTA and/or during treatment. These tests may check:

- the level of red and white blood cells and platelets in your body
- that your liver or kidneys are working properly
- the potassium levels in your blood

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Serious Drug Interactions

Do not take TWYNSTA with other blood pressure lowering drugs, including diuretics ("water pills"), aliskiren-containing products, or angiotensin-converting-enzyme inhibitors (ACEI) if you have diabetes (type 1 or type 2) or serious kidney problems. When taken together with TWYNSTA, they may cause very low blood pressure.

The following may interact with TWYNSTA:

- medicines that increase the levels of potassium in your blood. These include:

- salt substitutes that contain potassium
- potassium supplements
- potassium-sparing medicines
- heparin, used to thin the blood and prevent blood clots
- medicines that lower your blood pressure. These include:
 - diuretics (“water pills”)
 - aliskiren-containing medicines
 - angiotensin-converting-enzyme inhibitors (ACEI)
 - beta blockers
 - diltiazem, a calcium channel blocker
- antibiotics, used to treat bacterial infections, such as clarithromycin, erythromycin, rifampicin
- lithium, used to treat bipolar disease
- a class of medicines called nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and swelling, such as ASA, ibuprofen, naproxen, celecoxib
- a class of medicines called vasodilators, including nitrates, such as nitroglycerin used to treat chest pain
- corticosteroids, used to treat inflammation, taken by mouth or injection
- digoxin, used to treat heart problems
- warfarin, used to thin the blood to prevent blood clots
- medicines used to treat epilepsy, such as carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone
- medicines used to treat HIV/AIDS, such as ritonavir
- medicines used to treat fungal infections, such as ketoconazole, itraconazole
- medicines used to lower cholesterol, such as atorvastatin, simvastatin
- sildenafil, used to treat erectile dysfunction
- St. John’s Wort, an herbal medicine used to treat depression
- a class of medicines called mTOR inhibitors, used to prevent organ rejection, such as sirolimus, temsirolimus, everolimus
- medicines that suppress the immune system, such as cyclosporine, tacrolimus
- dantrolene, a muscle relaxant
- antidepressants
- medicines called barbiturates, used to help you sleep
- strong pain medicines called narcotics
- alcohol

How to take TWYNSTA:

- Take TWYNSTA:
 - exactly as prescribed
 - at about the same time everyday, preferably in the morning
 - swallowed whole, with water

- with or without food, but it should be taken the same way each day
- Remove your TWYNSTA tablet from the blister just before you take it.

Usual dose:

Your healthcare professional will decide the best dose for you based on your needs.

Overdose:

If you think you, or a person you are caring for, have taken too much TWYNSTA, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you have forgotten to take your dose during the day, carry on with the next one at the usual time. Do not double dose.

What are possible side effects from using TWYNSTA?

These are not all the possible side effects you may have when taking **TWYNSTA**. If you experience any side effects not listed here, tell your healthcare professional .

Side effects may include:

- dizziness, vertigo (feeling of spinning)
- drowsiness, insomnia, fatigue
- urge to urinate during the night
- rash, itching, skin discolouration, photosensitivity reaction
- increased sweating
- hair loss
- diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain, flatulence, change in bowel habits
- taste abnormalities
- swelling of the gums
- dry mouth
- headache, migraine
- anxiety, mood changes
- ringing in the ears
- back or leg pain, muscle cramps, spasms or stiffness, joint pain or swelling
- vision changes (double vision, blurred vision, etc.)
- upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), flu-like symptoms, cough, sneezing, runny nose, shortness of breath

- inability to have an erection (erectile dysfunction)
- enlargement of breasts in men
- changes in weight (increased or decreased)
- tingling or numbness of hands and feet

| Serious side effects and what to do about them | | | |
|---|--------------------------------------|--------------|---|
| Symptom / effect | Talk to your healthcare professional | | Stop taking drug and get immediate medical help |
| | Only if severe | In all cases | |
| COMMON | | | |
| Edema: unusual swelling of the arms, hands, legs, feet and ankles, face or airway passages | ✓ | | |
| UNCOMMON | | | |
| Low blood pressure: dizziness, fainting, light-headedness, trembling, flushing. May occur when you go from lying or sitting to standing up | | ✓ | |
| Slow heartbeat | | ✓ | |
| Palpitations (fast-beating, fluttering or pounding heart): skipping beats, beating too fast, pounding, fluttering rapidly | | ✓ | |
| Chest pain | | ✓ | |
| Rhabdomyolysis (breakdown of damaged muscle): muscle pain that you cannot explain, muscle tenderness or weakness, muscle cramps, dark red-brown urine | | ✓ | |
| Hyperkalemia (increased levels of potassium in the blood): irregular heartbeat, muscle weakness, generally feeling unwell | | ✓ | |
| Kidney disorder (including acute kidney failure): change in frequency of urination (little or no urine), dark urine, blood in urine, nausea, vomiting, loss of appetite, swelling of extremities, fatigue, thirst, dry skin, rash, irritability, mental status changes (drowsiness, confusion, coma) | | ✓ | |

| Serious side effects and what to do about them | | | |
|---|--------------------------------------|--------------|---|
| Symptom / effect | Talk to your healthcare professional | | Stop taking drug and get immediate medical help |
| | Only if severe | In all cases | |
| Cystitis (bladder infection): frequent or urgent urination, pain or burning when urinating, foul-smelling urine, cloudy or bloody urine, feeling unwell | ✓ | | |
| RARE | | | |
| Thrombocytopenia (decreased platelets): bruising, bleeding for longer than usual if you hurt yourself, fatigue and weakness | | ✓ | |
| Depression: low mood, feeling sad, loss of interest in activities, change in appetite and sleep patterns | | ✓ | |
| Hypoglycemia (low blood sugar): shaky, irregular or fast heartbeat, sweating, hunger, thirst, nausea and dizziness, frequent urination, nervousness, sweating, low energy | | ✓ | |
| Allergic reaction / Angioedema: wheezing, rash, hives, rapid swelling of the face, lips, tongue, throat, hands or feet, swelling of the digestive tract causing stomach pain, diarrhea, nausea or vomiting, difficulty swallowing or breathing, with a potentially fatal outcome | | | ✓ |
| Sepsis (infection of the blood): chills, confusion, fever or dizziness, high or very low body temperature, shakiness, irregular or rapid heartbeat, palpitations, rapid breathing, little or no urine, low blood pressure, with a potentially fatal outcome | | | ✓ |
| Hyponatremia (decreased sodium in the blood): lethargy, nausea, vomiting, abdominal cramps, agitation, confusion, muscle twitching, achy, stiff or uncoordinated muscles, seizure, coma | | ✓ | |

| Serious side effects and what to do about them | | | |
|---|--------------------------------------|--------------|---|
| Symptom / effect | Talk to your healthcare professional | | Stop taking drug and get immediate medical help |
| | Only if severe | In all cases | |
| UNKNOWN | | | |
| Severe skin reactions: fever, severe rash, swollen lymph glands, flu-like feeling, blisters and peeling skin that may start in and around the mouth, nose, eyes and genitals and spread to other areas of the body, yellow skin or eyes, shortness of breath, dry cough, chest pain or discomfort, feeling thirsty, urinating less often, less urine | | | ✓ |
| Liver disorder: yellowing of the skin or eyes, dark urine, abdominal pain, nausea, vomiting, loss of appetite, aches, tiredness, and a general ill feeling or flu-like symptoms | | ✓ | |
| Decreased white blood cells: frequent infections, fatigue, fever, chills, sore throat, aches, pains, flu-like symptoms | | ✓ | |
| Anemia (decreased levels of red blood cells): fatigue, loss of energy, weakness, looking pale, shortness of breath | | ✓ | |
| Pancreatitis (inflammation of the pancreas): upper abdominal pain, nausea, vomiting, fever, rapid heartbeat, tenderness when touching the abdomen | | ✓ | |
| Gastritis (inflammation of the stomach): nausea, vomiting, burping, bloating and feeling full after only a few bites of food | | ✓ | |
| Hyperglycemia (increased blood sugar): frequent urination, increased thirst and hunger, dry skin, headache, blurred vision, fatigue | | ✓ | |

| Serious side effects and what to do about them | | | |
|---|--------------------------------------|--------------|---|
| Symptom / effect | Talk to your healthcare professional | | Stop taking drug and get immediate medical help |
| | Only if severe | In all cases | |
| Vasculitis (inflammation of the blood vessels): fever, red raised spots caused by bleeding under the skin, aching muscles and joints, headache | | | ✓ |
| Myocardial infarction (heart attack): pressure or squeezing pain between the shoulder blades, in the chest, jaw, left arm or upper abdomen, shortness of breath, dizziness, fatigue, light-headedness, clammy skin, sweating, indigestion, anxiety, feeling faint and possible irregular heartbeat | | | ✓ |
| Extrapyramidal symptoms: muscle stiffness, body spasms, upward eye rolling, exaggeration of reflexes, drooling, difficulty moving how and when you want, tremors, involuntary facial movements | | | ✓ |

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at 15 - 30°C. Store in the original package in order to protect from moisture and light.

Do not use TWYNSTA after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Keep out of reach and sight of children.

If you want more information about TWYNSTA:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website (<https://www.boehringer-ingelheim.ca>), or by calling the manufacturer, Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.

This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The information in this leaflet is current up to the time of the last revision date shown below, but more current information may be available from the manufacturer.

Last Revised October 4, 2022